Pharmaceutical Industry The Best of Both Worlds: GEA Looks Back on Successful Business in China's Pharmaceutical Industry
Nearly two years after the acquisition of Beijing–based Sino-German Tianhe Technology, GEA Pharma Systems takes stock of its Chinese subsidiary: Since 2010, the newly created GEA Lyophil (Beijing) has quadrupled turnover and enhanced its customer service by blending German quality and Chinese economy for Asia's emerging pharmaceutical industry.
Beijing/PR China – Especially the introduction of GMP requirements for pharmaceutical productions have brught a change on China's pharma market, Jinbin Tang, MD of GEA Lyophil believes. This development has heated up the demand for pharmaceutical freeze drying lines, especially in combination with automatic load and unload systems (ALUS), a speciality of GEA Lyophil.
“The key for us is to make sure we use the facilities and talents of the Chinese and German manufacturing centres fully,” he explained.
The Best of Both Worlds
Heinrich Meintrup, Managing Director of GEA Lyophil in Germany agreed. “Having this combined option allows us to blend the benefits of German quality with a more cost-effective approach. We have never been willing to play the ‘low cost’ game, it just doesn’t work, but this quality/price performance model makes our offering unique.”
Customers Among Emerging Pharma Industry
GEA Lyophil's biggest customers in China are pharmaceutical companies who recognise that they need to use recognised, top-quality equipment to compete on their local market as well as on a world export stage.
“Most of our customers are making anti-cancer drugs, antibiotics or expensive biological products where top quality, security of outcome and reliable containment are essential,” said Jinbin Tang. “They consider our lines to represent the image of their companies.”
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 34959720)